Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental IllnessMAPS Canada Is Leading The Global Charge To Commercialize Psychedelic TherapiesBetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of DirectorsMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic MedicineTryp Therapeutics Partners with Alcami for Proprietary FormulationsHAVN Life Secures Production & Supply Agreement to Expand Retail Product OfferingsCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsNuminus Wellness Is One Of The Shining Stars Of The Psychedelic SectorPsychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream MediaMAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern MedicineRritual Superfoods Initiates Canadian Retail Growth Strategy Signing with Ultimate Sales CanadaNuminus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for SevTryp Therapeutics Partners with Clinlogix for Clinical Trial SupportTryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail Growth
Back

Cybin Corp: A Mushroom Life Sciences Leader In The Making

Jun 11, 2020 • 6:46 PM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Last month, we issued an update on Cybin Corp after having the opportunity to speak with members of the management team. Following our conversation, we felt much more comfortable with the business and want to provide a more in-depth look at the opportunity.

Cybin is a life sciences company that is focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market. The functional mushroom brand that is owned by the business is called Journey, which is a comprehensive line of functional mushroom products that contain adaptogens to support brain and body health.

One of the reasons we are excited about Cybin is due to the strength of the management team. The company is led by a management team that is comprised of industry veterans who have vast experience in the psychedelic, pharmaceutical, and nutraceutical sectors. The management team has previously successfully completed multiple clinical trials and has brought new drugs to market and find this to be an important aspect of the story.

Over the next year, we expect Cybin to record impressive growth and expect Journey to prove to be a major value driver for the business. Through the sale of nutraceutical products, Cybin will be able to support the growth and advancement of other verticals of the business.

Another reason we are excited about Cybin is due to the focus on furthering research and developing psilocybin-based medications through its wholly owned pharmaceutical division, Serenity Life Sciences. This vertical is focused on the development of a psilocybin therapy to treat depression, PTSD, addiction, and eating disorders. Before looking to partner or license its program to a larger pharmaceutical company, Cybin plans to conduct pre-clinical and clinical trials and we are favorable on the strategy that is in place.

Cybin has an attractive business model and has an intellectual property (IP) strategy that revolves around psychedelic delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new drug formulations, and protocol regimens. We believe that the business is focused on several high-growth verticals and are favorable on the ways its has been able to differentiate itself from other functional mushroom and psychedelic companies.

Earlier this year, Cybin announced a partnership with the Toronto Centre for Psychedelic Science to expand its psilocybin IP portfolio. We are favorable on the potential catalysts that are associated with on the partnership will monitor how the relationship benefits the business over the long-term.

Cybin is an early stage company that is laser focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors. The management team has been highly focused on executing on number of high growth initiatives and we believe that the team has laid the groundwork for future success.

If you are interested in learning more about Cybin and its focus on the functional mushroom and psychedelic therapy market, please send an email to support@mushroomstocks.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link